GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genexine Inc (XKRX:095700) » Definitions » Cyclically Adjusted Revenue per Share

Genexine (XKRX:095700) Cyclically Adjusted Revenue per Share : ₩818.26 (As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Genexine Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Genexine's adjusted revenue per share for the three months ended in Mar. 2024 was ₩50.013. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₩818.26 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Genexine's average Cyclically Adjusted Revenue Growth Rate was -4.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Genexine was 11.30% per year. The lowest was 8.40% per year. And the median was 9.85% per year.

As of today (2024-06-09), Genexine's current stock price is ₩7310.00. Genexine's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was ₩818.26. Genexine's Cyclically Adjusted PS Ratio of today is 8.93.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Genexine was 200.07. The lowest was 8.60. And the median was 53.11.


Genexine Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Genexine's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genexine Cyclically Adjusted Revenue per Share Chart

Genexine Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 612.04 660.58 808.36 844.60 842.45

Genexine Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 854.00 855.27 859.51 842.45 818.26

Competitive Comparison of Genexine's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Genexine's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genexine's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genexine's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Genexine's Cyclically Adjusted PS Ratio falls into.



Genexine Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Genexine's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=50.013/118.8477*118.8477
=50.013

Current CPI (Mar. 2024) = 118.8477.

Genexine Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 260.495 99.353 311.608
201409 289.495 99.608 345.412
201412 51.548 99.098 61.821
201503 148.118 99.720 176.529
201506 323.120 100.050 383.829
201509 33.004 100.110 39.181
201512 933.265 100.220 1,106.729
201603 259.014 100.560 306.118
201606 82.990 100.790 97.859
201609 27.428 101.460 32.128
201612 232.812 101.560 272.442
201703 88.959 102.850 102.796
201706 71.603 102.610 82.934
201709 232.148 103.490 266.598
201712 685.378 102.990 790.908
201803 68.068 104.100 77.711
201806 63.274 104.130 72.217
201809 75.093 105.650 84.474
201812 247.917 104.350 282.361
201903 22.039 104.490 25.067
201906 97.059 104.880 109.985
201909 142.598 105.200 161.097
201912 113.929 105.120 128.807
202003 232.762 105.540 262.111
202006 51.254 104.870 58.085
202009 15.800 106.200 17.682
202012 246.055 105.765 276.490
202103 1,332.100 107.357 1,474.675
202106 47.355 107.579 52.316
202109 7.102 108.759 7.761
202112 56.861 109.676 61.616
202203 310.263 111.806 329.804
202206 17.910 114.083 18.658
202209 68.338 114.831 70.728
202212 70.611 115.200 72.847
202303 19.241 116.550 19.620
202306 44.875 117.140 45.529
202309 8.878 119.111 8.858
202312 37.146 118.848 37.146
202403 50.013 118.848 50.013

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Genexine  (XKRX:095700) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Genexine's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=7310.00/818.26
=8.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Genexine was 200.07. The lowest was 8.60. And the median was 53.11.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Genexine Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Genexine's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Genexine (XKRX:095700) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genexine Inc (XKRX:095700) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
N/A
Address
700 Daewangpangyo-ro, Gyeonggi-do, Korea Bio Park Building B, Bundang-gu, Seongnam-si, KOR, 13488
Genexine Inc is a clinical-stage biotechnology company. It is focused on the development and commercialization of immunotherapeutics and next-generation long-acting biologics. Its primary technologies are Therapeutic DNA vaccine technology and Hyfc platform. The company's product pipeline includes products such as GX-H9, GX-E2, GX-G3, GX-G6, and Papitrol-188 among others.

Genexine (XKRX:095700) Headlines

No Headlines